Zydus Lifesciences Gets USFDA Approval For Jaythari Tablets; Zydus Share Spikes 

Share Market Today, Stocks in news: Zydus Lifesciences Limited has finally received approval from the USFDA (United States Food and Drug Administration) to manufacture Jaythari Tablets in the United States. This approval might help Zydus influence its global footprints in the US. Zydus Lifesciences share opened at ₹889.80 against its previous closing of ₹868.85. However, a consolidation takes place in the later session, bringing Zydus share price down to ₹872.15.

As per the experts, Zydus Lifescience shares opened higher amid the USFDA’s approval. This approval would help the company influence its revenue from the United States. Scroll down to learn more about the approval. 

USFDA Approval for Jaythari (Deflazacort) Tablets

Zydus Lifesciences Limited has received approval for Jaythari in different segments, such as 6MG, 18MG, 30MG, and 36MG. These tablets will be used to treat DMD (Duchenne Muscular Dystrophy) in patients aged 5 years and above. Jaythari (Deflazacort) helps improve muscle strength and slow the progression of muscle deterioration in DMD that would impact young males. 

Jaythari to Manufacture in Italy

Zydus Lifesciences Limited decided to manufacture Jaythari (Deflazacort) in Italy. The production of Jaythari in Italy would help Zydus meet the demand for tablets in the United States more efficiently. Also, this strategic move would ensure quality and compliance for the critical therapy. 

Expansion in Europe

Zydus Lifesciences announced the incorporation of its new step-down subsidiary “Zydus MedTech (France) SAS on 10th April 2025. This move reflects Zydus’s motive to strengthen its European operations in the MedTech segment. 

Effects of USFDA’s Approval For Jaythari (Deflazacort)

• Jaythari will offer low-cost treatment for US patients.
• The rare disease and oncology pipeline of Zydus would be strengthened. 
• DMD affects 1 in every 4000 male births globally. 

Impact of Zydus Share Price

On 11th April 2025 (Friday), Zydus Lifesciences share price rose 2.90% on the NSE (National Stock Exchange). And today, on 15th April 2025, the share price opened 2.41% up from its previous closing at ₹868.85. The company’s market capitalisation has increased to reach ₹87,366.00 crore. 

Final Thoughts

The UFSDA’s approval for Jaythari opened new doors for Zydus Lifesciences Limited in the rare disease market. It reinforced the company’s commitment to innovation and provided global access to life-saving treatments. Moreover, this strategic expansion in both the United States and Europe would make Zydus positioned for sustainable growth in 2025. 

For live stocks updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities. 

Explore Other News Articles

Stock Market Today: Sensex Opened 1,700 Points Up; Nifty Scales 23,368.35 | Check More Updates 

Stocks to Watch Today: 15th April 2025 | NHPC, HCL Tech, Tata Power, Cyient, PNB, & More!

Biocon Share Price in Focus Today: Biocon Gets FDA Approval for Bevacizumab Biosimilar

Stock Market Today: Sensex Jumps 1,100 Pts: Nifty Scales 22,800 as Gains Extend; Check Details

Stocks to Watch Today: 11th April 2025 | Sun Pharma, RITES, BHEL, TATA MOTORS, NBCC, SRF & More!

TCS Q4 Results Miss Estimates: Net Profit Down 2% YoY | ₹30 Dividend Declared

Tata Capital Files ₹15,000 Crore IPO via Confidential DRHP | Check All Details Here